# Manager, CMC Quality, Pulmovant at Pulmovant

> Remote · United States · Manager · Other · open. Source: https://alderhq.app/jobs/greenhouse%3Apulmovant%3A8303880 (read 2026-11-10).

## Facts (observed)

- Company: [Pulmovant](https://alderhq.app/companies/pulmovant)
- Location text: Remote, US; Pulmovant
- Where it can be done from (inferred): Remote · United States (evidence: "Remote role open worldwide")
- Posted: 2026-10-20 (21 days ago)
- First seen by alder: 2026-11-07 · last verified: 2026-11-08
- Reposted: 0 times · edited: 0 times
- Apply on the employer's site: https://job-boards.greenhouse.io/pulmovant/jobs/8303880

## Pay and sponsorship

- Posted pay: not posted
- Market band for similar posted roles (United States, n 7510): p25 $85k, median $133k, p75 $170k

## Description (the employer's text)

Pulmovant is a Roivant-backed clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases. Pulmovant’s first investigational candidate, mosliciguat, is designed to provide a novel, once-daily, inhaled treatment option for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Mosliciguat is a potential first-in-class soluble guanylate cyclase activator with a differentiated mechanism of action currently being evaluated in the Phase 3 PHrontier global clinical trial in PH-ILD, but with potential broad applicability across the PH and ILD disease landscape.

Pulmovant recently announced positive results from its Phase 2 PHocus study evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. PHocus met both primary and secondary endpoints including the highest ever reported pulmonary vascular resistance (PVR) reduction in any randomized controlled PH trial. The robust results, in conjunction with mosliciguat’s once-daily, inhaled administration and potential first-in-class sGC activator profile, strongly position it as a potential single agent treatment and combination therapy for patients with PH-ILD. These data represent a significant advancement in a devastating disease that affects ~200,000 patients with no or very limited treatment options. A Phase 3 trial is currently underway. More details can be found in the press release here.

As part of the Roivant family of companies, Pulmovant leverages the power of collaboration and innovation to drive progress.

For more information, please visit https://www.pulmovant.com.

About Roivant:

Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.

Position: Manager, CMC Quality

### Summary

The Manager, CMC Quality will support quality oversight of Pulmovant's vendors to ensure that drug substance, drug product, and finished product are manufactured, tested, released, and distributed in compliance with current Good Manufacturing Practices (cGMPs). Reporting to the Director, CMC Quality, this individual contributor role will focus on batch record review and product disposition for Pulmovant's global clinical development program. The role requires someone who thrives in a small-company environment and is comfortable being hands-on, with a practical, detail-oriented approach to release decisions and quality systems at external partners.

### Key Duties and Responsibilities

- Lead batch record review and clinical lot disposition for drug substance, drug product (inhaled), and clinical packaging and labeling, ensuring product is released in compliance with Pulmovant procedures, cGMPs, and applicable regional requirements.
- Support QP certification and release activities at contract manufacturing partners for ex-US clinical trials, including preparation of batch documentation packages and coordination of release timelines with CMOs, Supply Chain, and Clinical Operations.
- Review executed batch records, certificates of analysis, and associated testing data for accuracy, completeness, and conformance to master batch records, specifications, and registered/IND/IMPD commitments; drive timely resolution of documentation errors and gaps.

---
Data: alder (https://alderhq.app). Cite https://alderhq.app/jobs/greenhouse%3Apulmovant%3A8303880 and the date you read it. Observed facts come from the employer's own listing; location reach, level, family and skills are inferences.